Skip to main content
Trusted advisor to healthcare practitioners · Est. 2016

Practice Operations · For practice managers

How to Verify FDA Section 361 Compliance for Allografts

Published November 16, 2026

Regulatory Criteria
4 Core Requirements

Under 21 CFR 1271.10(a), an HCT/P must simultaneously meet all four statutory criteria—minimal manipulation, homologous use, no prohibited combinations, and no systemic cellular dependency—to qualify as a Section 361 product.

Registration Renewal Cadence
Annual Update

Registered HCT/P establishments are required by the FDA to update their registration annually in December and submit updates within 30 days if changes occur to their tissue processing listings.

Donor Screening Requirement
CLIA-Certified Labs

Compliant Section 361 allografts require communicable disease testing of donor specimens to be performed by laboratories certified under CLIA and registered with the FDA using FDA-licensed, approved, or cleared donor screening tests.

To verify FDA Section 361 compliance for tissue allografts, practice managers must confirm the processing laboratory holds an active FDA Human Cell and Tissue Establishment Registration (FEI number), review the manufacturer's regulatory documentation demonstrating adherence to all four criteria under 21 CFR 1271.10(a), and ensure marketing materials align strictly with homologous use. Because the FDA does not issue pre-market approval letters for Section 361 products, the burden of vendor qualification and documentation verification falls directly on the purchasing clinic and its distribution partners.

For clinics offering regenerative biologics—such as Wharton’s Jelly, amniotic tissue allografts, and cord blood products—navigating regulatory nuances is a core operational responsibility. While a medical director evaluates the clinical utility of a tissue product, the practice administrator must protect the enterprise from compliance liabilities, supply chain disruptions, and inventory seizures. Understanding how to vet suppliers before signing a purchasing agreement ensures your practice builds its regenerative service line on a stable, defensible foundation.

Understanding the Regulatory Divide: Section 361 vs. Section 351

Human cells, tissues, and cellular and tissue-based products (HCT/Ps) are regulated under 21 CFR Part 1271. The FDA divides these products into two distinct regulatory tiers based on risk and processing methodology.

Section 361 HCT/Ps are regulated solely under Section 361 of the Public Health Service (PHS) Act. These products focus primarily on preventing the introduction, transmission, and spread of communicable diseases. If a tissue product meets all the criteria in 21 CFR 1271.10(a), it does not require pre-market FDA approval (such as a Biologics License Application or Investigational New Drug application) to be commercially distributed.

Section 351 HCT/Ps are products that fail to meet one or more of the Section 361 criteria. Because they may be more than minimally manipulated or intended for non-homologous use, the FDA regulates them as drugs, devices, and/or biological products under the Federal Food, Drug, and Cosmetic Act. Commercial distribution of a Section 351 product requires an approved BLA or an active IND.

When a vendor markets a Section 351 product as if it were an exempt Section 361 tissue, both the manufacturer and the purchasing clinic face regulatory exposure. Therefore, knowing how to verify FDA Section 361 compliance for tissue allografts is a mandatory step in medical procurement.

The Four Pillars of 21 CFR 1271.10(a)

To qualify as a Section 361 HCT/P, a tissue allograft must simultaneously satisfy four statutory criteria. Practice managers should familiarize themselves with these definitions when reviewing vendor dossiers:

  1. Minimal Manipulation: For structural tissue (such as amniotic membrane or umbilical cord tissue), processing must not alter the original relevant characteristics of the tissue relating to its utility for reconstruction, repair, or replacement. For cells or nonstructural tissues, processing must not alter the relevant biological characteristics.
  2. Homologous Use Only: The product must perform the same basic function or functions in the recipient as in the donor, as reflected by the labeling, advertising, and other objective intent of the manufacturer.
  3. No Combination with Other Articles: The manufacture of the HCT/P must not involve the combination of the cells or tissues with another article, with limited exceptions for water, crystalloids, or sterilizing, preserving, or storage agents that do not raise new clinical safety concerns.
  4. No Systemic Effect (With Exceptions): Either the HCT/P does not have a systemic effect and is not dependent upon the metabolic activity of living cells for its primary function, or, if it does, it is intended for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.

Step-by-Step Procurement Checklist: Verifying Vendor Compliance

When evaluating a new biologics manufacturer or distributor, practice administrators should request a standardized compliance packet. Use the following checklist to audit the documentation before placing an initial order.

  • Verify the FDA Establishment Registration (FEI Number): Access the public FDA Human Cell and Tissue Establishment Registration database online. Search the processing laboratory by legal name or FEI number to confirm its registration is active and lists the specific tissue types you intend to purchase.
  • understand What Registration Means: Never accept an FDA registration certificate as proof of "FDA Approval." Establishment registration simply means the facility has notified the FDA of its operations and is subject to inspection; it is not an endorsement of the product's regulatory classification.
  • Confirm AATB Accreditation and State Licensing: Request current accreditation certificates from the American Association of Tissue Banks (AATB), which sets rigorous industry standards for tissue banking. Additionally, check for state-specific tissue bank licenses from jurisdictions with strict oversight (such as New York, California, Florida, or Maryland), as well as appropriate distributor licensing (for example, confirming your distributor holds an active state medical device or tissue distribution license, as Dallas Regenerative Solutions does in Texas).
  • Audit Donor Eligibility and Infectious Disease Testing: Review a sample Certificate of Analysis (COA) or package insert. Confirm that donor screening complies with 21 CFR 1271 Subpart C and takes place in a CLIA-certified, FDA-registered laboratory testing for relevant communicable disease agents (HIV, Hepatitis B and C, syphilis, WNV, Zika, and others).
  • Evaluate Processing Methodology: Request the manufacturer’s white paper or regulatory rationale letter explaining how their processing preserves the structural integrity of the tissue (minimal manipulation). Be cautious of structural tissues that have been enzymatically digested or micronized in a way that destroys the extracellular matrix, unless supported by clear FDA Tissue Reference Group (TRG) feedback.
  • Inspect Labeling and Marketing Materials for Objective Intent: Review the vendor's website, brochures, and package inserts. The FDA determines "homologous use" based on the manufacturer's objective intent. If a vendor's sales representative or brochure claims an amniotic allograft will cure systemic diseases or regenerate specific organ systems, that marketing can reclassify the product into the Section 351 drug category.
  • Check the FDA Warning Letter Database: Perform a quick search of the FDA’s enforcement database for the processor's name and its parent companies. A history of Untitled Letters or Warning Letters regarding unapproved HCT/Ps is a critical red flag.

Clinical Considerations for Physicians and Medical Directors

While the practice manager handles vendor vetting and chain-of-custody logistics, the clinical application of allografts rests with the treating physician. For clinicians in orthopedics, pain management, and regenerative medicine, regulatory compliance intersects directly with clinical charting and informed consent.

Physicians must understand the distinction between structural support and cellular therapy. Under current FDA guidance, structural allografts like Wharton’s Jelly and amniotic membranes are regulated as Section 361 tissues when used to provide a protective covering, cushion, or structural barrier. Even if a physician exercises clinical judgment within the practice of medicine, the practice’s own patient-facing marketing—including website copy, social media, and intake forms—must not make unapproved drug claims or promise guaranteed clinical outcomes.

Furthermore, clinicians should align their clinical documentation with the biological properties of the allograft. Charting should accurately reflect the lot number, expiration date, tissue source, and the structural or cushioning rationale for the placement, ensuring seamless traceability from the tissue bank to the patient record.

Operational Workflow: Receiving, Cold-Chain, and Traceability

Compliance does not end once a vendor passes your initial procurement audit. Under Current Good Tissue Practice (CGTP), the receiving clinic must maintain strict operational protocols to preserve tissue integrity and patient safety.

  1. Cold-Chain Verification Upon Receipt: Cryopreserved biologics typically arrive in dry ice shippers or liquid nitrogen dry vapor shippers. Front-desk or clinical staff must inspect the shipment immediately upon arrival, verify that coolant remains, and transfer the vials to the appropriate ultra-low temperature freezer or cryogenic storage tank according to the package insert.
  2. Tissue Tracking Logs: Practices must maintain a centralized tissue log that records the date of receipt, shipping condition, product identifier/lot number, storage temperature logs, and the final disposition (patient identifier and date of application, or destruction record).
  3. Tissue Warranty Cards: Most compliant tissue processors include a tissue transplant record or warranty card with every allograft. Completing and returning this documentation to the processor closes the traceability loop, which is essential in the rare event of an adverse reaction investigation or lot recall.

What This Means for Your Practice

Integrating tissue allografts into your clinical offerings requires a disciplined approach to vendor management. To protect your practice and streamline procurement, implement these immediate action steps:

  • Standardize Your Vendor Onboarding File: Create a physical or digital compliance binder containing the FEI registration printout, AATB certificate, CLIA lab certifications, and sample COAs for every biologics line stored in your clinic.
  • Audit Your Practice Marketing: Review your clinic’s website and patient brochures with your medical director to ensure you are not inadvertently making Section 351 drug claims about Section 361 structural tissues.
  • Consolidate Through Vetted Distributors: Rather than auditing dozens of independent labs, partner with an established distributor that conducts rigorous due diligence on its manufacturing partners and provides transparent documentation for every product.

If your practice is currently evaluating tissue allografts, exosomes, or regenerative devices and needs assistance verifying vendor documentation or optimizing per-procedure costs, our team can help. Contact Dallas Regenerative Solutions to schedule a procurement consultation and review our compliance-vetted portfolio.

Frequently asked questions

Does an FDA FEI number mean a tissue allograft is FDA-approved?
No. An FDA Establishment Identifier (FEI) number simply confirms that the tissue establishment has registered its facility and listed its products with the FDA under 21 CFR Part 1271. Section 361 HCT/Ps are exempt from pre-market approval, meaning they are neither FDA-approved nor FDA-cleared; any vendor claiming "FDA approval" for a Section 361 allograft is misrepresenting its regulatory status.
What are the four criteria for an HCT/P to be regulated under Section 361?
Under 21 CFR 1271.10(a), the tissue must be minimally manipulated, intended for homologous use only, not combined with another article (aside from approved preserving or storage agents), and must not have a systemic effect or depend on the metabolic activity of living cells for its primary function (unless used autologously, in a first- or second-degree blood relative, or for reproductive use). All four conditions must be met simultaneously.
How can a practice manager verify a tissue bank's FDA registration?
Practice managers can access the public FDA Human Cell and Tissue Establishment Registration (HCTERS) database online. By entering the processing laboratory's legal name or FEI number, you can confirm whether their registration is currently active, see which specific tissue categories they are registered to process, and verify their physical location.
What happens if a vendor makes disease-treatment claims about a Section 361 allograft?
Under FDA regulations, a product's homologous use is determined in part by the manufacturer's "objective intent," which includes labeling, advertising, and oral or written statements by sales representatives. If a vendor promotes a tissue allograft to treat or cure specific systemic diseases rather than for structural support or cushioning, the FDA may reclassify the product as an unapproved Section 351 biological drug.
What records must a medical practice keep after purchasing Section 361 allografts?
Practices should maintain a complete chain-of-custody log for every tissue product received. This includes shipping receipt logs confirming cold-chain integrity, daily freezer or refrigerator temperature logs, lot numbers, expiration dates, patient chart linking for traceability, and completed tissue tracking cards returned to the processor.

Bring regenerative medicine into your practice.

Talk with our team about biologics, devices, or an AI-powered peptide protocol tailored to your patients.

Request Consultation →